NIOX GroupCSSPF 77 FCF Margin % is 33.19% as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, NIOX Group ranks better than 96.93% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NIOX Group's Free Cash Flow for the
six
months ended in Dec. 2025 was $10.44 Mil. NIOX Group's Revenue for the
six
months ended in Dec. 2025 was $31.46 Mil. Therefore, NIOX Group's FCF Margin % for the quarter that ended in Dec. 2025 was 33.19%.
The historical rank and industry rank for NIOX Group's FCF Margin % or its related term are showing as below:
CSSPF'
s FCF Margin % Range Over the Past 10 Years
Min: -248.48 Med: -40.3 Max: 38.76
Current: 28.51
During the past 13 years, the highest FCF Margin % of NIOX Group was 38.76%. The lowest was -248.48%. And the median was -40.30%.
CSSPF's FCF Margin % is ranked better than 96.93% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs CSSPF: 28.51
NIOX Group FCF Margin % Related Terms
NIOX Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for NIOX Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where NIOX Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a FCF Margin % of 33.19% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #25 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 3.1%.
Is NIOX Group's FCF Margin % too high?
NIOX Group's current FCF Margin % is 33.19%. Based on the distribution chart, NIOX Group ranks #25 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #25 out of 815 companies for FCF Margin %. This places NIOX Group in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NIOX Group and its competitors. NIOX Group's current FCF Margin % is 33.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current FCF Margin % is 33.19%. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For NIOX Group (CSSPF), the current FCF Margin % is 33.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
FCF Margin %: 33.19%
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
